EPOPROSTENOL 0.5mg powder + solvent infusion solution medication leaflet

B01AC09 epoprostenol • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin

Epoprostenol is a medication used to treat severe pulmonary arterial hypertension, a condition that affects the blood vessels in the lungs and can lead to heart failure. This medicine works by dilating the blood vessels in the lungs, reducing pressure and improving the patient's exercise capacity. Epoprostenol is usually administered by continuous intravenous infusion under strict medical supervision.

Treatment with epoprostenol requires close monitoring, as the dose must be adjusted based on the patient's response and any side effects. It is important for patients to strictly follow the doctor's instructions and report any new or unusual symptoms.

Side effects may include headaches, facial flushing, nausea, diarrhea, or jaw pain. In rare cases, infections at the catheter site or severe drops in blood pressure may occur.

Epoprostenol is an essential treatment for patients with severe pulmonary arterial hypertension, but it requires continuous medical supervision to ensure the therapy's effectiveness and safety. Collaboration with the medical team is crucial for treatment success.

General data about EPOPROSTENOL 0.5mg

Substance: epoprostenol

Date of last drug list: 01-05-2019

Commercial code: W64161001

Concentration: 0.5mg

Pharmaceutical form: powder + solvent infusion solution

Quantity: 1

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: MERCURY PHARMACEUTICALS LTD - MAREA BRITANIE

Holder: PHARMNET PLUS S.R.L. - ROMANIA

Number: 351/2018/01

Shelf life: 3 years